News Sobi pays $1.5bn for Arthrosi to grow in gout Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.
News SanegeneBio raises $110m for RNAi, plus other financings Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.
News Agreement reached on EU's new pharma legislation Agreement has been reached on the reform of EU pharma legislation, but industry thinks it does not go far enough to restore the bloc's global status.
News Lilly's obesity triple pulls off 29% weight loss in trial Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.
News AC Immune says Parkinson's drug slows progression AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.
News Pfizer makes first-line case for Tukysa in breast cancer Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.